Eureka Therapeutics Receives Orphan Drug Designation for ET140203
Eureka Therapeutics has received an Orphan Drug designation for its investigational therapy ET140203 for the treatment of hepatoblastoma, a rare liver tumor that usually occurs in children under five years old.
The cell therapy involves the collection of a patient’s T cells which are modified to express Eureka’s proprietary ARTEMIS T cells — the acronym stands for antibody redirected T cells with endogenous modular immune signaling — and are then infused back into the patient. The ARTEMIS T cells are designed to target specific types of cancer.
The company is recruiting patients in three phase 1/2 clinical trials to investigate the efficacy and safety of ARTEMIS T cells, including one pediatric study evaluating ET140203.
The FDA grants Orphan Drug status to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States.
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1 for adults and ARYA2 for pediatrics) and ECT204 (ARYA3), in Phase I/II US trials in patients with advanced liver cancer. Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area.
October 21, 2022
